<SEC-DOCUMENT>0001004878-17-000135.txt : 20170615
<SEC-HEADER>0001004878-17-000135.hdr.sgml : 20170615
<ACCEPTANCE-DATETIME>20170614181309
ACCESSION NUMBER:		0001004878-17-000135
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20170613
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20170615
DATE AS OF CHANGE:		20170614

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		17912077

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8kitem801endinvest6-17.txt
<DESCRIPTION>8-K RE CLOSE INVESTIGATION
<TEXT>
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (date of earliest event reported): June 13, 2017

                             CEL-SCI CORPORATION
                             -------------------
            (Exact name of Registrant as specified in its charter)



         Colorado                    01-11889                  84-0916344
----------------------------    ---------------------    ---------------------
(State or other jurisdiction    (Commission File No.)       (IRS Employer
of incorporation)                                        Identification No.)


                         8229 Boone Boulevard, Suite 802
                             Vienna, Virginia 22182
                      -----------------------------------
          (Address of principal executive offices, including Zip Code)


      Registrant's telephone number, including area code: (703) 506-9460

                                       N/A
                       ----------------------------------
         (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-14(c) under the
     Exchange Act (17 CFR 240.13e-4(c))



<PAGE>


Item 8.01   Other Events

     By letter  dated  June 13,  2017 the  Securities  and  Exchange  Commission
notified the Company that it had concluded its  investigation as to the Company,
and that,  based on the  information  the Commission has as of June 13, 2017, it
does not intend to recommend an enforcement action by the Commission against the
Company. The Commission provided this notice to the Company under the guidelines
set out in the final paragraph of Securities Act Release No. 5310,  which states
in part that the notice  "must in no way be  construed  as  indicating  that the
party has been  exonerated  or that no action  may  ultimately  result  from the
staff's investigation."



<PAGE>



                                   SIGNATURES


      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:  June 14, 2017

                                      CEL-SCI CORPORATION


                                      By: /s/ Patricia B. Prichep
                                          ---------------------------------
                                          Patricia B. Prichep
                                          Senior Vice President of Operations



</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
